Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Autosomal recessive cerebellar ataxia-27 caused by a novel loss-of-function variant of ganglioside-induced differentiation associated protein 2 in a Spanish family

  • Erro Aguirre, María Elena
  • Martí-Andrés, Gloria
  • Alvira-Iraizoz, Fernando
  • Vicente Cemborain, Esther
  • Pérez-Juana del Casal, Aranzazu
  • Bengoa-Alonso, Amaya
  • Ramos Arroyo, María A.
  • García Solaesa, Virginia
Background and ObjectivesOur aim has been to describe a patient with a novel loss-of-function variant of the ganglioside-induced differentiation associated protein 2 (GDAP2) gene in homozygosis causing autosomal recessive cerebellar ataxia.MethodsWe studied the virtual gene panel of hereditary ataxia with onset in adulthood (version 4.15) of PanelApp by means of whole exome sequencing. The validation of the variant of interest found was performed by Sanger sequencing. A segregation study was performed on family members.ResultsThe patient is a man who started at age 32 years with dysarthria soon followed by cerebellar ataxia. On evolution, spasticity, cervical dystonia, and cognitive impairment were observed. A premature stop codon variant was detected in homozygosity in exon 2 of the GDAP2 gene: c.57_59delinsACCCCAGCT (p.Trp19*). It was also detected in the patient's mother and brother, who were heterozygous, and 4 nephews on the paternal side, who were also carriers of the variant.DiscussionThis null variant in the GDAP2 gene has not been previously described in the literature associated to ataxia, neither is it present in population databases. It is considered probably pathogenic (PVS1 and PM2) and as such can be classified from this study, providing further evidence on the association of GDAP2 with hereditary cerebellar ataxia., This study was partially supported by the Health Department of Navarre Government (project 19-2021), co-funded (50%) by the European Regional Development Fund through the Navarre ERDF 2014-2020 Operative Programme.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Epidemiology of progressive supranuclear palsy in Navarre, Spain: a population-based study

  • Arrondo Gómez, Pablo
  • Vicente Cemborain, Esther
  • Martí-Andrés, Gloria
  • Sánchez Ruiz de Gordoa, Javier
  • Gaston Zubimendi, Itziar
  • Clavero Ibarra, Pedro Luis
  • Valentí Azcarate, Rafael
  • Delfrade Osinaga, Josu
  • Erro Aguirre, María Elena
Background: Epidemiological studies carried out on progressive supranuclear palsy (PSP) provide heterogeneous data. Our aim has been to analyze incidence, point prevalence, survival, and time to diagnosis of PSP in Navarre, a northern Spanish region. Methods: This is a population-based observational retrospective study from 2010 to 2022. Data from various sources of health information were reviewed to identify all potential diagnoses of PSP, validated through medical records reviews. Patients were included if they fulfilled the 2017 Movement Disorder Society (MDS) criteria and were classified into the different PSP phenotypes. Results: A total of 226 prevalent PSP cases were identified. Age-standardized point prevalence rate at January 1, 2023, was 7.52/100,000 inhabitants, and age-standardized annual incidence rate (IR) for the period was 2.41/100,000 person-years. PSP-Richardson syndrome (RS) phenotype showed significantly higher prevalence and incidence rates compared to PSP non-RS phenotypes. Joinpoint regression for overall incidence showed a significant increase until 2018 and thereafter a significant steep decline. Joinpoint regression for prevalence showed a statistically significant annual decline from 2018 onwards. Mortality rate experienced a peak in 2020. Median time to diagnosis was 37 months, and the median survival from clinical symptom onset was 89 months. PSP-RS was associated with reduced time to diagnosis and reduced survival compared to the PSP non-RS phenotypes. Conclusions: This study represents the first population-based epidemiological study of PSP in Spain and the first with application of the new MDS diagnostic criteria in Europe, providing detailed incidence, prevalence, and mortality data that are in accordance with other European studies., This study was partially supported by the Health Department ofthe Navarre Government [project 19-2021], co-funded (50%) by theEuropean Regional Development Fund (ERDF) through the NavarreERDF 2014-2020 Operative Programme.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Variably protease-sensitive prionopathy: two new cases with motor neuron-dementia syndrome

  • Erro Aguirre, María Elena
  • Zelaya Huerta, María Victoria
  • Eraña, Hasier
  • Sánchez Ruiz de Gordoa, Javier
  • García Amigot, Fermín
  • Simonovska-Serra, Anika
  • Caballero Martínez, María Cristina
  • Ferrer, Isidro
  • Gelpi, Ellen
  • Jericó Pascual, Ivonne
  • Castilla, Joaquín
We describe two patients with variably protease-sensitive prionopathy (VPSPr) who developed progressive upper motor neuron symptoms, insomnia, behavioral and cognitive decline, compatible with primary lateral sclerosis associated with frontotemporal dementia (FTD). Neuropathology revealed a spongiform encephalopathy with frontotemporal and pronounced thalamic involvement, associated with fine synaptic abnormal prion protein conformer (PrPSc) deposits, microplaques, and intraneuronal aggregates. Western blot analysis revealed a characteristic VPSPr proteolytic profile, lacking the diglycosylated band. Both patients were methionine homozygous at PRNP codon 129 and carried no pathogenic mutations. These cases illustrate that VPSPr can present with a prominent motor neuron syndrome and FTD features., This work was supported by the Health Department of Navarre Government (19-2021), European Regional Development Fund, Federal Ministry Labour, Social Affairs, Health, Care and Consumer Protection, and Agencia Estatal de Investigacion, Ministerio de Ciencia e Innovacion (PID2021-122201OB-C21, PID2024-160022OB-I00), that also granted a Severo Ochoa Excellence accreditation (CEX2021-001136-S) to the CIC bioGUNE. This study was also supported by the project EFA031/01, NEURO-COOP, co-funded at 65% by the European Union (Regional Development Funds) through the Interreg VI-Spain-France-Andorra Programme (POCTEFA 2021-2027).